Moelis & Company

The stock is in a constructive recovery phase after a long base, trading above its 200-day average and near the middle of its 52-week range rather than pressing the highs. That keeps the setup positive but not extended, with room to rebuild toward the prior peak if momentum holds.

Street sentiment is cautious-to-mixed: consensus sits at Hold, while the average target of 75.75 still leaves upside from current levels. Recent revisions have turned softer, led by UBS cutting its view to Sell and trimming its target to 60, even as a few firms remain constructive.

The earnings profile has been strong overall, with 6 of the last 7 quarters beating EPS estimates. Next quarter is expected to show $0.60 EPS, and full-year estimates point to $3.07 for 2026 versus $3.89 for 2027, so shareholders should watch whether advisory activity supports that step-up.

No discretionary insider buying or selling stands out. Recent activity is dominated by director award grants, which are compensation-related rather than conviction signals, so the pattern reads neutral rather than bullish or bearish.

Profitability is strong, led by a 92.3% gross margin and 41.8% ROE, though earnings growth has been softer than revenue growth. Revenue rose 4.3% year over year while earnings fell 23.7%, showing the business is still highly profitable but not immune to deal-cycle pressure.

Moelis wins on margin quality and cash generation versus most capital-markets peers, with a 12.3% FCF yield and net cash of $241.4 million. Valuation is not cheap on an absolute basis at 23.58x earnings, but it remains tied to a premium advisory franchise rather than a balance-sheet story.